Selenium in the treatment of autoimmune thyroiditis

We recently conducted a prospective, placebo‐controlled clinical study, where we could demonstrate, that a substitution of 200 μg sodium selenite for three months in patients with autoimmune thyroiditis reduced thyroid peroxidase antibody (TPO‐Ab) concentrations significantly. Forty‐seven patients f...

Full description

Saved in:
Bibliographic Details
Published in:BioFactors (Oxford) 2003, Vol.19 (3-4), p.165-170
Main Authors: Gärtner, Roland, Gasnier, Barbara C. H.
Format: Article
Language:English
Subjects:
Adult
Antioxidants - therapeutic use
Autoantibodies - blood
autoimmune thyroiditis
clinical trial
Cross-Over Studies
Female
Follow-Up Studies
Humans
Iodide Peroxidase - blood
Iodide Peroxidase - drug effects
Middle Aged
Prospective Studies
selenium
Selenium - therapeutic use
thyroglobulin antibody
thyroid peroxidase antibody
Thyroiditis, Autoimmune - blood
Thyroiditis, Autoimmune - drug therapy
Thyroiditis, Autoimmune - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We recently conducted a prospective, placebo‐controlled clinical study, where we could demonstrate, that a substitution of 200 μg sodium selenite for three months in patients with autoimmune thyroiditis reduced thyroid peroxidase antibody (TPO‐Ab) concentrations significantly. Forty‐seven patients from the initially 70 patients agreed to participate in a follow‐up cross‐over study for further six months. One group (n = 13), which initially received selenium continued to take 200 μg sodium selenite (Se‐Se), one group stopped taking selenium (Se‐0) ( n = 9), another group which received placebo started to take 200 μg selenium (n = 14) (Plac‐Se) and the last group was without selenium substitution (Plac‐0) (n = 11). TPO‐Ab concentrations were measured at beginning and the end of the study. In the Se‐Se group, the TPO‐Ab concentrations further significantly p = 0.004) decreased from 625 ± 470 U/ml to 354 ± 321 U/ml, in the Se‐0 group the TPO‐Ab concentrations increased significantly p = 0.017) from 450 ± 335 to 708 ± 313 U/ml. In the placebo group, the TPO‐Ab concentrations in those patients who were followed without selenium substitution were unchanged (1351 ± 940 vs. 1724 ± 1112 U/ml, p = 0.555). In contrast, the patients who received 200 μg sodium selenite after placebo, the TPO‐Ab concentrations decreased significantly (p = 0.029) from 1182 ± 723 to 643 ± 477 U/ml.
ISSN:0951-6433
1872-8081
DOI:10.1002/biof.5520190309